Related Experiment Video

Updated: May 2, 2026

Glucose-Stimulated Insulin Secretion via Perfusion through the Mice Vasculature with an Intact Pancreas
04:41

Glucose-Stimulated Insulin Secretion via Perfusion through the Mice Vasculature with an Intact Pancreas

Published on: July 25, 2025

1.2K

[Glucose lowering drugs in case of impaired renal function]

Marijke A J Assink1, Alferso C Abrahams, Maarten B Rookmaaker

  • 1Universitair Medisch Centrum Utrecht, afd. Nefrologie en Hypertensie, Utrecht.

Nederlands Tijdschrift Voor Geneeskunde
|March 13, 2014
PubMed

Insights

Optimal anti-diabetic drug use in type 2 diabetes mellitus (DM2) requires considering renal function. Guidelines lack specifics for impaired kidneys, necessitating evaluation of drug pharmacokinetics and clinical data for safe and effective DM2 management.

Area of Science:

  • Nephrology
  • Endocrinology
  • Pharmacology

Background:

  • Type 2 diabetes mellitus (DM2) affects 20-40% of patients with renal impairment.
  • Current evidence-based guidelines lack specific recommendations for anti-diabetic drug use in DM2 patients with impaired renal function.
  • Renal impairment impacts both drug pharmacokinetics and glucose metabolism.

Purpose of the Study:

  • To evaluate the applicability of individual anti-diabetic drugs in patients with DM2 and renal impairment.
  • To provide guidance on drug selection and dosing based on renal function.
  • To highlight drugs that can be dosed independently of renal function.

Main Methods:

  • Review of pharmacokinetic properties of anti-diabetic drugs.
  • Analysis of clinical experience with anti-diabetic drugs in renal impairment.
  • Categorization of drug applicability based on creatinine clearance levels.

Main Results:

  • For DM2 patients with creatinine clearance ≥ 60 ml/min/1.73 m2, standard anti-diabetic drug doses are applicable.
  • For DM2 patients with creatinine clearance < 60 ml/min/1.73 m2, certain drugs are contraindicated, and others require dose adjustment.
  • A subset of anti-diabetic medications allows for dosing independent of renal function.

Conclusions:

  • Drug selection and dosing in DM2 patients with renal impairment must consider individual drug pharmacokinetics and clinical data.
  • Renal function is a critical factor in determining safe and effective anti-diabetic therapy.
  • Tailored therapeutic strategies are necessary for DM2 patients with varying degrees of renal impairment.

More Related Videos

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice10:31

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice

Published on: May 2, 2025

798
Assessment of Kidney Function in Mouse Models of Glomerular Disease09:16

Assessment of Kidney Function in Mouse Models of Glomerular Disease

Published on: June 30, 2018

21.0K

Related Concept Videos

Oral Hypoglycemic Agents: &#945;-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
953
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
993
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
1.0K
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
671
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
371